The platform includes is a live Salmonella-based typhoid vaccine Typhella and genetic technology spi-VEC developed by Emergent. Prokarium will combine this with its own ORT-vac expression platform to create an oral vaccine delivery platform, named Vaxonella.
Prokarium plans to license the delivery platform to other biotechnology companies, while its in-house team will use it to develop a dual oral vaccine against typhoid and travellers’ diarrhoea.